After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
Boehringer discontinues brigimadlin while others continue to struggle.
The THIO-104 study listing is live, along with questions about funding the trial.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
